NEW YORK, June 27 (Reuters) - Shares of Auxilium Pharmaceuticals Inc AUXL.O could fall if bullish projections for the market size of its new hand treatment fail to pan out, according to an article in the June 28 edition of Barron‘s.
Auxilium’s Xiaflex was approved by the U.S. Food and Drug Administration in February for a hand condition known as Dupuytren’s contracture.
According to the article, while evidence supporting Xiaflex’s effectiveness is strong, the evidence for the amount of patients that might be out there is weak and contradictory.
Auxilium shares, which closed on Friday at $24.79, could fall into the teens, the article said.
Reporting by Lewis Krauskopf, editing by Martin Golan